Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.

Journal of thrombosis and haemostasis : JTH - 1 Jun 2006

McCORMACK W M, Seiler M P, Bertin T K, Ubhayakar K, Palmer D J, Ng P, Nichols T C, Lee B

Abstract excerpt

BACKGROUND: Adenoviral vector-mediated gene therapy might have potential for long-term correction of the monogenic disease hemophilia A. OBJECTIVE: In this study, we tested the efficacy of administering a helper-dependent adenoviral vector (HDV) designed for maximal liver-restricted canine factor VIII (cFVIII) expression on three out-bred hemophilia A dogs. METHODS: Three FVIII-deficient animals from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Blood Coagulation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Factor VIII

Share to Genetic Therapy

Share to Genetic Vectors

Share to Hemophilia A

Share to Partial Thromboplastin Time

Source

Open in PubMed Open full text

Identifiers

PMID: 16706963
DOI: 10.1111/j.1538-7836.2006.01901.x
PMCID: PMC3947717

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.PMID 16706963Read ↗

Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.Semantic proximity Read ↗

Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector.Semantic proximity Read ↗

A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.Semantic proximity Read ↗

Balloon Catheter Delivery of Helper-dependent Adenoviral Vector Results in Sustained, Therapeutic hFIX Expression in Rhesus MacaquesSemantic proximity Read ↗

Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.Semantic proximity Read ↗

AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of lifeSemantic proximity Read ↗

Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.Semantic proximity Read ↗

Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia ASemantic proximity Read ↗

Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.Semantic proximity Read ↗

Protein Replacement Therapy and Gene Transfer in Canine Models of Hemophilia A, Hemophilia B, von Willebrand Disease, and Factor VII DeficiencySemantic proximity Read ↗

Gene therapy for the hemophilias.Semantic proximity Read ↗

Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.